# Chronic Disease Management Protocols for Direct Primary Care

## 2.1 COPD Management Protocol

### Initial Diagnosis and Assessment

#### Diagnostic Criteria
- Post-bronchodilator FEV1/FVC < 0.70
- Compatible symptoms: dyspnea, chronic cough, sputum production
- Risk factor exposure (smoking, occupational, pollution)

#### GOLD Classification
- **GOLD 1 (Mild):** FEV1 ≥80% predicted
- **GOLD 2 (Moderate):** 50% ≤ FEV1 <80% predicted
- **GOLD 3 (Severe):** 30% ≤ FEV1 <50% predicted
- **GOLD 4 (Very Severe):** FEV1 <30% predicted

#### Initial Workup
1. Spirometry with bronchodilator response
2. Chest X-ray
3. CBC, BMP
4. Alpha-1 antitrypsin level (if <45 years or family history)
5. Assessment tools: CAT score, mMRC dyspnea scale

### Management Protocol

#### Non-Pharmacologic Management
1. **Smoking Cessation:** (Priority #1)
   - Behavioral counseling
   - Nicotine replacement therapy
   - Varenicline or bupropion
   - CPT: 99406-99407 (smoking cessation counseling)

2. **Pulmonary Rehabilitation:**
   - Refer if mMRC ≥2 or CAT ≥10
   - Exercise training program
   - Breathing techniques
   - Nutritional counseling

3. **Vaccinations:**
   - Annual influenza vaccine
   - PPSV23 and PCV13/PCV15/PCV20
   - COVID-19 vaccination series
   - Tdap

#### Pharmacologic Management

**Group A (Low Risk, Few Symptoms):**
- Short-acting bronchodilator PRN
- Albuterol MDI 2 puffs q4-6h PRN

**Group B (Low Risk, More Symptoms):**
- LAMA or LABA
- Tiotropium 18mcg daily OR
- Formoterol 12mcg BID

**Group E (High Risk):**
- LABA + LAMA (preferred) OR
- LABA + ICS if blood eos ≥300 cells/μL
- Consider triple therapy if frequent exacerbations

#### Exacerbation Management
**Mild Exacerbation (Outpatient):**
- Prednisone 40mg daily x 5 days
- Antibiotics if increased sputum purulence:
  - Azithromycin 500mg x 1, then 250mg x 4 days
  - Doxycycline 100mg BID x 7 days
- Increase bronchodilator frequency

**Monitoring Schedule:**
- Stable COPD: Every 3-6 months
- Post-exacerbation: Within 1-2 weeks
- Annual spirometry
- Assess inhaler technique each visit

**CPT Codes:**
- 99213-99214 (routine follow-up)
- 94010 (spirometry)
- 94060 (bronchodilator response)

---

## 2.2 Heart Failure Management Protocol

### Diagnosis and Classification

#### Initial Workup
1. **Laboratory:**
   - BNP or NT-proBNP
   - CBC, CMP, TSH
   - Lipid panel
   - HbA1c
   - Urinalysis

2. **Imaging:**
   - Chest X-ray
   - Echocardiogram (essential)
   - ECG

#### Classification
**NYHA Functional Classification:**
- Class I: No limitation
- Class II: Slight limitation
- Class III: Marked limitation
- Class IV: Symptoms at rest

**ACC/AHA Stages:**
- Stage A: At risk
- Stage B: Structural disease, no symptoms
- Stage C: Structural disease with symptoms
- Stage D: Refractory HF

### Management Protocol

#### HFrEF Management (EF ≤40%)

**Foundational Therapy (All patients):**
1. **Beta-blocker:**
   - Carvedilol 3.125mg BID, titrate to 25mg BID
   - Metoprolol succinate 25mg daily, titrate to 200mg daily

2. **ACE-I/ARB/ARNI:**
   - Lisinopril 2.5-5mg daily, titrate to 40mg daily
   - OR Sacubitril/valsartan 49/51mg BID, titrate to 97/103mg BID

3. **MRA:**
   - Spironolactone 12.5-25mg daily (if GFR >30, K+ <5.0)

4. **SGLT2 Inhibitor:**
   - Dapagliflozin 10mg daily OR
   - Empagliflozin 10mg daily

**Additional Therapies:**
- Loop diuretic for volume overload
- Hydralazine/isosorbide dinitrate in African Americans
- Digoxin for persistent symptoms
- ICD/CRT per guidelines

#### HFpEF Management (EF ≥50%)
1. **Diuretics for volume overload**
2. **SGLT2 inhibitor**
3. **Treat comorbidities:**
   - Hypertension
   - Atrial fibrillation
   - Obesity
   - Sleep apnea

#### Monitoring Protocol
1. **Every Visit:**
   - Weight, BP, heart rate
   - Volume status assessment
   - Symptom review
   - Medication adherence

2. **Laboratory Monitoring:**
   - BMP: 1-2 weeks after medication changes, then q3-6 months
   - BNP: Baseline and with clinical changes
   - Annual: CBC, LFTs, TSH

3. **Self-Management Education:**
   - Daily weights
   - Sodium restriction (<2g/day)
   - Fluid restriction if indicated
   - Exercise program
   - When to call provider

**CPT Codes:**
- 99214-99215 (complex management)
- 93306 (echocardiogram)
- 83880 (BNP)

---

## 2.3 Chronic Pain Management (Non-Opioid Focus)

### Assessment Protocol

#### Initial Evaluation
1. **Comprehensive Pain History:**
   - Location, quality, intensity (0-10 scale)
   - Timing, triggers, alleviating factors
   - Functional impact
   - Previous treatments
   - Psychosocial factors

2. **Screening Tools:**
   - PHQ-9 for depression
   - GAD-7 for anxiety
   - DAST-10 for substance use
   - PEG scale for ongoing monitoring

3. **Physical Examination:**
   - Focused musculoskeletal exam
   - Neurological assessment
   - Functional assessment

### Non-Opioid Management Strategies

#### Pharmacologic Options

**First-Line Agents:**
1. **NSAIDs:**
   - Ibuprofen 400-800mg TID
   - Naproxen 500mg BID
   - Consider PPI for GI protection

2. **Acetaminophen:**
   - 650-1000mg QID (max 3g/day)
   - Avoid in liver disease

3. **Topical Agents:**
   - Diclofenac gel 1% QID
   - Lidocaine 4-5% patches
   - Capsaicin 0.025-0.075%

**Second-Line Agents:**
1. **Neuropathic Pain:**
   - Gabapentin 100-300mg TID, titrate to effect
   - Pregabalin 75mg BID
   - Duloxetine 30-60mg daily

2. **Muscle Relaxants:**
   - Cyclobenzaprine 5-10mg TID
   - Tizanidine 2-4mg TID
   - Limit to 2-3 weeks

#### Non-Pharmacologic Interventions

1. **Physical Therapy:**
   - Refer for ≥6 sessions
   - Home exercise program
   - CPT: 97110-97140

2. **Behavioral Interventions:**
   - CBT for chronic pain
   - Mindfulness-based stress reduction
   - Biofeedback

3. **Complementary Approaches:**
   - Acupuncture
   - Massage therapy
   - Yoga/Tai Chi

4. **Interventional Options:**
   - Trigger point injections
   - Joint injections
   - Nerve blocks (refer)

#### Monitoring and Follow-up
- Initial follow-up: 2-4 weeks
- Stable patients: Every 1-3 months
- Use PEG scale for tracking
- Document functional goals

**CPT Codes:**
- 99213-99214 (follow-up visits)
- 20552-20553 (trigger point injections)
- 20610 (major joint injection)

---

## 2.4 Thyroid Disorder Management

### Hypothyroidism Management

#### Diagnosis
- TSH >4.5 mIU/L with low free T4
- Subclinical: TSH 4.5-10 mIU/L with normal free T4

#### Initial Workup
1. TSH, free T4
2. TPO antibodies (if autoimmune suspected)
3. Lipid panel
4. CBC

#### Treatment Protocol
1. **Levothyroxine Dosing:**
   - Young/healthy: 1.6 mcg/kg/day
   - Elderly/cardiac disease: Start 25-50 mcg/day
   - Pregnancy: Increase dose by 30%

2. **Monitoring:**
   - TSH at 6-8 weeks after initiation/dose change
   - Annual TSH when stable
   - Goal TSH: 0.5-2.5 mIU/L (younger patients)
   - Goal TSH: 4-6 mIU/L (elderly)

3. **Administration Instructions:**
   - Take on empty stomach
   - 30-60 minutes before breakfast
   - Separate from calcium, iron by 4 hours

### Hyperthyroidism Management

#### Initial Workup
1. TSH, free T4, free T3
2. TSI or TSH receptor antibodies
3. Thyroid ultrasound
4. Radioactive iodine uptake if needed

#### Treatment Options
1. **Anti-thyroid Drugs:**
   - Methimazole 10-40mg daily (preferred)
   - PTU 100mg TID (pregnancy first trimester only)

2. **Beta-blockers for Symptoms:**
   - Propranolol 10-40mg TID
   - Atenolol 25-100mg daily

3. **Monitoring:**
   - TSH, free T4 every 4-6 weeks initially
   - CBC, LFTs at baseline and if symptoms
   - Refer for definitive treatment consideration

### Thyroid Nodule Management
1. **TSH + Ultrasound for all nodules**
2. **FNA Indications:**
   - >1cm with suspicious features
   - >1.5cm with intermediate features
   - >2cm with benign features
3. **Follow-up based on Bethesda classification**

**CPT Codes:**
- 99213-99214 (thyroid management)
- 84443 (TSH)
- 84439 (free T4)

---

## 2.5 Osteoporosis Screening and Treatment

### Screening Protocol

#### Screening Indications
1. **All women ≥65 years**
2. **Postmenopausal women <65 with risk factors:**
   - BMI <21
   - Parental hip fracture
   - Smoking
   - >3 alcoholic drinks/day
   - Rheumatoid arthritis
   - Glucocorticoid use

3. **Men ≥70 years**
4. **Adults ≥50 with fracture**

#### Diagnostic Testing
- DEXA scan of hip and spine
- FRAX calculation for 10-year fracture risk
- Consider: Vitamin D, calcium, CBC, CMP, TSH

### Treatment Protocol

#### Non-Pharmacologic Management
1. **Calcium:** 1200mg daily (diet + supplement)
2. **Vitamin D:** 800-1000 IU daily
3. **Exercise:** Weight-bearing and resistance
4. **Fall prevention:** Home safety assessment
5. **Lifestyle:** Smoking cessation, limit alcohol

#### Pharmacologic Treatment Indications
- T-score ≤-2.5
- T-score -1.0 to -2.5 with FRAX ≥3% (hip) or ≥20% (major)
- Previous fragility fracture

#### First-Line Medications
1. **Bisphosphonates:**
   - Alendronate 70mg weekly
   - Risedronate 35mg weekly
   - Zoledronic acid 5mg IV annually

2. **Administration Instructions:**
   - Take on empty stomach with 8oz water
   - Remain upright 30 minutes
   - Nothing by mouth for 30 minutes

#### Monitoring
- DEXA every 2 years on treatment
- Bone turnover markers optional
- Assess adherence and side effects
- Drug holiday after 5 years if low risk

**CPT Codes:**
- 77080 (DEXA scan)
- 99213-99214 (osteoporosis management)
- 96372 (injection administration)

---

## 2.6 Metabolic Syndrome Protocol

### Diagnostic Criteria (≥3 of 5)
1. Waist circumference: >40 inches (men), >35 inches (women)
2. Triglycerides: ≥150 mg/dL
3. HDL: <40 mg/dL (men), <50 mg/dL (women)
4. Blood pressure: ≥130/85 mmHg
5. Fasting glucose: ≥100 mg/dL

### Management Protocol

#### Lifestyle Interventions (First-Line)
1. **Weight Loss Goal:** 5-10% of body weight
2. **Diet:**
   - Mediterranean or DASH diet
   - Reduce simple carbohydrates
   - Increase fiber, whole grains
   - Limit saturated fat

3. **Exercise:**
   - 150 minutes moderate aerobic/week
   - 2 days resistance training/week
   - 10,000 steps daily goal

4. **Behavioral Support:**
   - Referral to dietitian
   - Consider weight loss program
   - Apps for tracking

#### Pharmacologic Management

**Dyslipidemia:**
- Statin therapy per cardiovascular risk
- Consider fibrate if TG >500 mg/dL

**Hypertension:**
- ACE-I/ARB first-line
- Target <130/80 mmHg

**Dysglycemia:**
- Metformin 500mg BID, titrate to 1000mg BID
- Consider if prediabetic with BMI >35

**Weight Management:**
- Consider GLP-1 agonists
- Orlistat 120mg TID with meals

### Monitoring
- Weight, waist circumference each visit
- Lipids, glucose annually
- Blood pressure each visit
- ALT at baseline and periodically

**CPT Codes:**
- 99214 (complex management)
- 97802-97804 (nutrition counseling)
- 99401-99404 (preventive counseling)

---

## 2.7 Fatty Liver Disease Management

### Diagnosis and Staging

#### Initial Evaluation
1. **Laboratory:**
   - LFTs (ALT, AST, Alk phos, bilirubin)
   - CBC, CMP
   - Lipid panel, HbA1c
   - Hepatitis B/C screening
   - Iron studies
   - Consider: ANA, anti-smooth muscle Ab

2. **Imaging:**
   - Ultrasound (first-line)
   - Consider FibroScan
   - CT/MRI if needed

3. **Risk Stratification:**
   - Calculate FIB-4 score
   - <1.3: Low risk
   - 1.3-2.67: Intermediate
   - >2.67: High risk (refer)

### Management Protocol

#### Lifestyle Modifications
1. **Weight Loss:**
   - Goal: 7-10% body weight
   - 500-1000 kcal/day deficit
   - Low-carb or Mediterranean diet

2. **Exercise:**
   - 150-300 minutes/week moderate intensity
   - Resistance training 2x/week

3. **Avoid:**
   - Alcohol
   - High fructose corn syrup
   - Processed foods

#### Medical Management
1. **Diabetes Control:**
   - Metformin first-line
   - Consider pioglitazone
   - GLP-1 agonists showing benefit

2. **Dyslipidemia:**
   - Statins safe and beneficial
   - Monitor LFTs

3. **Vitamin E:**
   - 800 IU daily for non-diabetic NASH
   - Not for diabetics or cirrhosis

### Monitoring
- ALT every 3-6 months
- Annual: FIB-4, metabolic panel
- Ultrasound every 2-3 years
- Refer to hepatology if:
  - FIB-4 >2.67
  - Persistent ALT elevation >6 months
  - Signs of cirrhosis

**CPT Codes:**
- 99213-99214 (NAFLD management)
- 76700 (abdominal ultrasound)
- 91200 (liver elastography)